Since both forms are recognized by the CT-1 antibody, they must possess most, if not all, of the C-terminal sequence. inhibitors indicating the formation of CTF15: nicastrin complexes. MUC1CTF15 accumulation in response to -secretase inhibition was exhibited in both normal and tumor-derived cells from humans and mice indicating that this processing pathway exists in many cell contexts. We did not detect products of MUC1 cleavage by -secretase in the presence of numerous proteasomal inhibitors indicating that subsequent degradation is usually either non-proteasomal or extremely efficient. We suggest that this efficient pathway attenuates potential signaling mediated by cytoplasmic tail fragments. Keywords:MUC1, -SECRETASE, ENDOMETRIUM, EMBRYO IMPLANTATION MUC1 is usually a greatly glycosylated type I transmembrane protein expressed at the apical surface of many normal ITGB2 secretory epithelial cells [Gendler, 2001]. Due to its elevated expression in a variety of human malignancies and its ensuing oncogenic potential [Hanisch and Muller, 2000;von Mensdorff-Pouilly et al., 2000], YW3-56 considerable effort has been expended in determining MUC1s suitability as both a prognostic indication for disease progression and therapeutic target for disease attenuation. Inherent to the success of these efforts is an understanding of the metabolic events by which a tumor cell processes MUC1, how these events differ from those occurring in normal cells, and how these differences may contribute to the initiation, maintenance, and/or progression of the pathologic state. Full length MUC1 (MUC1F) is composed of three structural YW3-56 domains: (i) an extracellular domain name (ECD) made up of extensivelyO-glycosylated tandem repeat YW3-56 20 amino acid sequences; (ii) a hydrophobic transmembrane domain name (TMD) and; (iii) a cytoplasmic tail domain name (CTD). MUC1F in the beginning is usually synthesized as a single polypeptide chain in both normal and malignant cells. Shortly after synthesis in the endoplasmic reticulum, MUC1 undergoes an autoproteolytic cleavage within the SEA module located within the ECD, 58 amino acids beyond the N-terminus of the TMD [Levitin et al., 2005;Macao et al., 2006]. The producing two subunits form a heterodimer [Ligtenberg et al., 1992] through a stable non-covalent association (metabolic complex) that persists as MUC1 transits through the golgi apparatus, undergoing O-glycosylation, and arriving at the cell surface [Ligtenberg et al., 1992;Julian and Carson, 2002]. The ectodomain made up of the tandem repeats is usually released from a subset of cell surface MUC1F. MUC1F ECD release is dependent on the activity of at least two sheddases, TACE/ADAM 17 [Thathiah et al., 2003] and MT1-MMP [Thathiah and Carson, 2004]. No soluble form of MUC1F ECD is usually released in the absence of sheddase activity in normal cells. Even though association of the two subunits of the MUC1F metabolic complex is usually theoretically reversible, dissociation under physiologic conditions has not been demonstrated. However, NM23-H1, released into medium only from tumor-derived cells, interacts with the ECD portion of MUC1F C-terminal subunit, disrupting the metabolic complex and displacing the N-terminal subunit [Mahanta et al., 2008]. While early studies focused on the fate YW3-56 of the MUC1 ECD, current interest has centered on processing and the ultimate fate of the TMD and CTD of MUC1F. The potential involvement YW3-56 of the MUC1 CTD in signaling events, both indirectly via activation of signaling pathways [Schroeder et al., 2001;Lillehoj et al., 2004;Thompson et al., 2006] and directly when translocated to the nucleus [Li et al., 2003;Singh et al., 2007] or mitochondria [Ren et al., 2004,2006], necessitates elucidation of the intervening metabolic events. Translocation to both intracellular locales requires internalization followed by transport, presumably endosomal. Endosomal transport has been established only for internalization of MUC1 C-terminal subunit initiated by ligand engagement of EGF receptor [Pochampalli et al., 2007;Liu et al., 2008]. Yet translocation to any intracellular.